LUGPA 2024
Stay up to date with the latest coverage of the LUGPA 2024 Annual Meeting.
In the final segment of the roundtable, the panel debates the real-world integration of new therapies into everyday practice.
In part five of this NMIBC roundtable, the panelists discuss integrating new therapies such as TAR-200 into clinical practice
Part four of this roundtable series examines the SunRISe-1 trial results for high-risk NMIBC.
The panelists discuss advancements in NMIBC treatment in part three of this roundtable, including pembrolizumab and TAR-200.
Part two of this roundtable explores intravesical and systemic therapies, and the importance of accurate risk stratification.
The first part of this roundtable focuses on recent trial data, the role of TUR quality, and precision medicine for NMIBC.
Dr. Brown shares highlights from the CME program at LUPGA 2024, including new trends in bladder, kidney, and prostate cancer.
Dr. Jayram breaks down important topics in kidney cancer from LUGPA 2024, including adjuvant pembrolizumab post-nephrectomy.
Dr. Jayram provides insights into the BCG-unresponsive and BCG-naive bladder cancer space at the LUGPA 2024 Annual Meeting.
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
Advertisement
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get conference updates straight to your inbox.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.